BlackRock Inc. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,350,046 shares of the specialty pharmaceutical company's stock, valued at approximately $434,871,000. BlackRock Inc. owned approximately 16.08% of Supernus Pharmaceuticals at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. increased its holdings in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock worth $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $51,000. Hantz Financial Services Inc. grew its position in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock worth $54,000 after buying an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $55,000.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on SUPN. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $62.83.
Read Our Latest Research Report on Supernus Pharmaceuticals
Supernus Pharmaceuticals Trading Up 0.6%
Shares of NASDAQ SUPN opened at $45.36 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $42.45 and a 12-month high of $59.68. The stock's fifty day simple moving average is $46.80 and its two-hundred day simple moving average is $48.78. The stock has a market capitalization of $2.64 billion, a PE ratio of -23.62, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56.
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company's revenue was up 32.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.40 earnings per share. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.
Supernus Pharmaceuticals Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
